Breban M., Fernandez-Sueiro JL, Richardson JA, Havdavand RR, Maika SD, Hammer RE, and Taurog JD (1996). T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J. Immunol. 156: 794-803.
2.
Breban M., Hammer RE, Richardson JA, and Taurog JD (1993). Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment. J. Exp. Med. 178: 1607-1616.
3.
Cotran RS, Kumar V, and Robbins SL (eds) ( 1994). Pathologic Basis of Disease. W. B. Saunders, Philadelphia, pp. 1253-1254.
4.
Hammer RE, Maika SD, Richardson JA, Tang J., and Taurog JD (1990). Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2m: An animal model of HLA-B27-associated human disorders. Cell63: 1099-1112.
5.
Hammer RE, Richardson JA, Simmons WA, White AL, Breban M., and Taurog JD (1995). High prevalence of colorectal cancer in HLA-B27 transgenic F344 rats with chronic inflammatory bowel disease. J. Invest. Med. 43: 262-268.
6.
Taurog JD, Lowen L., Forman J., and Hammer RE (1988). HLA-B27 in inbred and noninbred transgenic mice. Cell surface expression and recognition as an alloantigen in the absence of human β2-microglobulin. J. Immunol. 141: 4020-4023.
7.
Taurog JD, Maika SD, Simmons WA, Breban M., and Hammer RE (1993). Susceptability to inflammatory disease in HLA-B27 transgenic rats correlates with level of B27 expression. J. Immunol. 150: 4168-4178.
8.
Yanagisawa H. , Richardson JA, Taurog JD, and Hammer RE (1995). Characterization of psoriasiform and alopecic skin lesions in HLA-B27 transgenic rats. Am. J. Pathol. 147: 955-964.
